1. Scrip
  2. >>Business
  3. >>Financing

IFM Therapeutics ‘Lather, Rinse, Repeat’ Strategy On Track With $55M Financing

 
• By Jessica Merrill

The drug discovery company with a big pharma deal-making track record is launching a new subsidiary, IFM Quattro, and a drug discovery incubator, IFM Discovery. Scrip talked to IFM's new CEO Martin Seidel about what is ahead for the company.

close up foam in two hand isolated on white background. - Image
IFM Therapeutics is lathering up its next round of drug discovery • Source: Shutterstock

After completing two lucrative business deals with Bristol-Myers Squibb Co. and Novartis AG, privately-held drug discovery firm IFM Therapeutics LLC is doubling down on the strategy with plans to deliver more novel drugs into the hands of big pharma. The company announced on 2 December the completion of a $55.5m financing that it will use to launch a new subsidiary, IFM Quattro, and a drug discovery incubator, IFM Discovery.

It is an impressive new financing round for a company that has already delivered multiple deals with big pharma partners in just four years

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Gilead Joins Pharma’s US Investment Rush

 
• By Alaric DeArment

The company drew praise from the Trump administration as one of multiple companies announcing multibillion-dollar investments in US manufacturing and R&D.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic

 
• By Mandy Jackson

HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.